A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • OBJECTIVES: To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma. METHODS: This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine carcinoma (cohort A) and uterine carcinosarcoma (cohort B). Eligibility criteria included measurable disease, 0-1 prior chemotherapy regimens, and ECOG performance status


  • Nimeiri, Halla S
  • Oza, Amit M
  • Morgan, Robert J
  • Huo, Dezheng
  • Elit, Laurie
  • Knost, James A
  • Wade, James L
  • Agamah, Edem
  • Vokes, Everett E
  • Fleming, Gini F

publication date

  • April 2010

has subject area